Rakovina Therapeutics Inc
RKV.V
Toronto Stock Exchange Ventures0.27
CAD
+0.02
- -
Rakovina Therapeutics Inc
RKV.V
(Toronto Stock Exchange Ventures)
Recent
price
0.27
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rakovina Therapeutics Inc. operates as a clinical-stage biopharmaceutical research company focused on the discovery and development of precision oncology therapies targeting the DNA-damage response (DDR). The Company applies proprietary and artificial intelligence-enabled drug-discovery technologies to identify, optimize and develop small-molecule cancer therapeutics intended to exploit vulnerabilities in tumor DNA-repair pathways, with the objective of advancing selected candidates into human clinical trials and pursuing development partnerships with pharmaceutical companies. Rakovina Therapeutics’ principal programs comprise the kt-5000AI series of AI-designed, CNS-penetrant dual ATR/mTOR inhibitors for genetically defined and treatment-resistant cancers, including PTEN-deficient tumors; the kt-2000AI program of AI-generated PARP-targeting compounds for preclinical in vitro and in vivo validation; and the kt-3000/kt-3283 program, which combines the bifunctional PARP/HDAC inhibitor kt-3283 with lipid nanoparticle delivery technology. The Company’s research and development activities include computational drug design; medicinal chemistry; lead generation and optimization; pharmacokinetic, absorption, distribution, metabolism and excretion testing; in vitro and in vivo efficacy studies; lipid nanoparticle formulation development; and preclinical safety and candidate-selection activities. Its target customers and collaborators include pharmaceutical and biotechnology companies pursuing oncology assets and DDR-focused therapeutic programs. Rakovina Therapeutics was founded in 2020 and is headquartered in Vancouver, British Columbia, Canada. In 2026, the Company expanded its collaboration with Variational AI to continue optimizing the kt-5000 dual ATR/mTOR inhibitor series using Variational AI’s Enki generative AI platform; continued formulation and preclinical evaluation work for kt-3283 with NanoPalm Ltd., including NanoPalm’s EnsaliX-designed patterned lipid nanoparticle platform; and reported preclinical AACR data showing antitumor activity, metabolic stability, selectivity, CNS penetration and improved tolerability for kt-5000 candidates, as well as successful characterization of a kt-3283 lipid nanoparticle formulation. The Company also completed an upsized non-brokered private placement in August 2026 that raised aggregate gross proceeds of approximately C$1.99 million, with proceeds designated primarily for in vivo ADME and efficacy studies for kt-5000AI, continued AI-driven lead optimization with Variational AI, advancement of the kt-3000 lipid nanoparticle program, continued kt-2000AI compound development and general working capital.
Company News
Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development